Oral bioavailability of etoposide after administration of a single dose to tumor-bearing dogs

American Journal of Veterinary Research

Volumn 69, Issue 10, 2008, Pages 1316-1322

  Flory, Andrea B ^a,c   Rassnick, Kenneth M ^a   Balkman, Cheryl E ^a   Kiselow, Michael A ^a   Autio, Karoliina ^a,d   Beaulieu, Bernard B ^b   Lewis, Lionel D ^b  

^a Department of Obstetrics Gynecology   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c ANIMAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOG DISEASE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HYPERSENSITIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOG DISEASES; DOGS; ETOPOSIDE; INFUSIONS, INTRAVENOUS; KINETICS; NEOPLASMS;

ANIMALIA; CANIS FAMILIARIS;

EID: 56049116967     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.69.10.1316     Document Type: Article

References (41)

1. Montecucco A, Biamonti G. Cellular response to etoposide treatment. Cancer Lett 2007;252:9-18.
2. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998;34:1514-1521.
3. Ross W, Rowe T, Glisson B, et al. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 1984;44:5857-5860.
4. Long BH, Musial ST, Brattain MG. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res 1985;45:3106-3112.
5. Slevin ML, Clark PI, Joel SP et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989;7:1333-1340.
6. McLeod HL, Relling MV Stability of etoposide solution for oral use. Am J Hosp Pharm 1992;49:2784-2785.
7. Mathew P, Ribeiro RC, Sonnichsen D, et al. Phase I study of oral etoposide in children with refractory solid tumors. J Clin Oncol 1994;12:1452-1457.
8. Edick MJ, Gajjar A, Mahmoud HH, et al. Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol 2003;21:1340-1346.
9. Hohenhaus AE, Matus RE. Etoposide (VP-16). Retrospective analysis of treatment in 13 dogs with lymphoma. J Vet Intern Med 1990;4:239-241.
10. Ogilvie GK, Cockburn CA, Tranquilli WJ, et al. Hypotension and cutaneous reactions associated with intravenous administration of etoposide in the dog (Erratum published in Am J Vet Res 1988;49:1765). Am J Vet Res 1988;49:1367-1370.
11. Masini E, Planchenault J, Pezziardi F, et al. Histamine-releasing properties of polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. Agents Actions 1985;16:470-477.
12. Gough WB, Zeiler RH, Barreca P, et al. Hypotensive action of commercial intravenous amiodarone and polysorbate 80 in dogs. J Cardiovasc Pharmacol 1982;4:375-380.
13. McEntee M, Silverman JA, Rassnick K, et al. Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. Vet Comp Oncol 2003;1:105-112.
14. Pommier Y, Goldwater F. Topoisomerase inhibitors: the epipodophyllotoxins, acridines, and ellipticines. In: Chabner BA, Longo DL, eds. Cancer chemotherapy and biotherapy: principles and practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2005;451-475.
15. Veterinary co-operative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:195-213.
16. Robieux I, Aita P, Sorio R, et al. Determination of unbound etoposide concentration in ultrafiltered plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr B Biomed Appl 1996;686:35-41.
17. Kato Y, Mawatari H, Nishimura S, et al. Determination of etoposide serum concentrations in small pediatric samples by an improved method of reversed-phase high-performance liquid chromatography. Acta Med Okayama 2003;57:21-24.
18. Stewart DJ, Nundy D, Maroun JA, et al. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. Cancer Treat Rep 1985;69:269-273.
19. Cunningham D, McTaggart L, Soukop M, et al. Etoposide: a pharmacokinetic profile including an assessment of bioavailability. Med Oncol Tumor Pharmacother 1986;3:95-99.
20. Slevin ML, Joel SP, Whomsley R, et al. The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation. Cancer Chemother Pharmacol 1989;24:329-331.
21. Hainsworth JD, Johnson DH, Frazier SR, et al. Chronic daily administration of oral etoposide - a phase I trial. J Clin Oncol 1989;7:396-401.
22. Hainsworth JD, Williams SD, Einhorn LH, et al. Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial. J Clin Oncol 1985; 3:666-671.
23. Hande KR, Krozely MG, Greco FA, et al. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993;11:374-377.
24. Igwemezie LN, Kaul S, Barbhaiya RH. Assessment of toxicokinetics and toxicodynamics following intravenous administration of etoposide phosphate in beagle dogs. Pharm Res 1995;12:117-123.
25. Eisenberg EJ, Eickhoff WM. Determination of etoposide in blood by liquid chromatography with electrochemical detection. J Chromatogr 1993;621:110-114.
26. Lana S, U'ren L, Plaza S, et al. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med 2007;21:764-769.
27. Wolff SN, Grosh WW, Prater K, et al. In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy. Cancer Chemother Pharmacol 1987;19:246-249.
28. Drewinko B, Barlogie B. Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213. Cancer Treat Rep 1976;60:1295-1306.
29. Heck MM, Hittelman WN, Earnshaw WC. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci U S A 1988;85:1086-1090.
30. Fox ME, Smith PJ. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone. Cancer Res 1990;50:5813-5818.
31. Allen JD, Brinkhuis RF, Wijnholds J, et al. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999;59:4237-4241.
32. Leu BL, Huang JD. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 1995;35:432-436.
33. Keller RP, Altermatt HJ, Donatsch P, et al. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int J Cancer 1992;51:433-438.
34. Allen JD, Van Dort SC, Buitelaar M, et al. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res 2003;63:1339-1344.
35. Yahanda AM, Alder KM, Fisher GA, et al. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1992;10:1624-1634.
36. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992;10:1635-1642.
37. Shah JC, Chen JR, Chow D. Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. Pharm Res 1989;6:408-412.
38. Boothe DM. Veterinary compounding in small animals: a clinical pharmacologist's perspective. Vet Clin North Am Small Anim Pract 2006;36:1129-1173.
39. Reif S, Nicolson MC, Bisset D, et al. Effect of grapefruit juice intake on etoposide bioavailability. Eur J Clin Pharmacol 2002; 58:491-494.
40. Clark PI, Slevin ML, Joel SP, et al. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 1994;12:1427-1435.
41. Toutain PL, Bousquet-Melou A. Bioavailability and its assessment. J Vet Pharmacol Ther 2004;27:455-466.